The predictive value of inflammatory and oxidative markers following the successful cardioversion of persistent lone atrial fibrillation

International Journal of Cardiology

Volumn 135, Issue 3, 2009, Pages 361-369

  Leftheriotis, Dionyssios I ^a   Fountoulaki, Katerina T ^a   Flevari, Panayota G ^a   Parissis, John T ^a   Panou, Fotis K ^a   Andreadou, Ioanna T ^b   Venetsanou, Koula S ^c   Iliodromitis, Efstathios K ^a   Kremastinos, Dimitrios Th ^a  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c KAT HOSPITAL   (Greece)

Author keywords

Atrial fibrillation; Inflammation; Oxidative stress; Prognosis

Indexed keywords

3 NITROTYROSINE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 6; MALONALDEHYDE; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ARTICLE; CARDIOVERSION; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HOLTER MONITORING; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PREDICTIVE VALIDITY; PRIORITY JOURNAL; RECURRENCE RISK; RELIABILITY; SINUS RHYTHM; SYMPTOMATOLOGY;

ADULT; ATRIAL FIBRILLATION; BIOLOGICAL MARKERS; COHORT STUDIES; ELECTRIC COUNTERSHOCK; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; MALE; MIDDLE AGED; OXIDATIVE STRESS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 67349230831     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2008.04.012     Document Type: Article

References (39)

1. Goette A., Lendeckel U., and Klein H.U. Signal transduction systems and atrial fibrillation. Cardiovasc Res 54 (2002) 247-258
2. Leftheriotis D.I., Theodorakis G.N., Poulis D., et al. The effects of 5-HT4 receptor blockade and stimulation, during six hours of atrial fibrillation. Europace 7 (2005) 560-568
3. Bruins P., te Velthuis H., Yazdanbakhsh A.P., et al. Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation 96 (1997) 3542-3548
4. Chung M.K., Martin D.O., Sprecher D., et al. C-reactive protein elevation in patients with atrial arrhythmias. Inflammatory mechanisms and persistence of atrial fibrillation. Circulation 104 (2001) 2886-2891
5. Frustaci A., Chimenti C., Bellocci F., Morgante E., Russo M.A., and Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 96 (1997) 1180-1191
6. Mihm M.J., Yu F., Carnes C.A., et al. Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation 104 (2001) 174-180
7. Shiroshita-Takeshita A., Brundel B., Lavoie J., and Nattel S. Prednisone prevents atrial fibrillation promotion by atrial tachycardia remodeling in dogs. Cardiovasc Res 69 (2006) 865-875
8. Shiroshita-Takeshita A., Schram G., Lavoie J., and Nattel S. Effect of simvastatin and antioxidant vitamins on atrial fibrillation promotion by atrial- tachycardia remodeling in dogs. Circulation 110 (2004) 2313-2319
9. Fuster V., Ryden L.E., Cannom D.S., et al. Task Force on Practice Guidelines, American College of Cardiology/American Heart Association; Committee for Practice Guidelines, European Society of Cardiology; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. Eur Heart J 22 (2001) 1852-1923
10. Halligan S.C., Gersh B.J., Brown R.D., et al. The natural history of lone atrial fibrillation. Ann Intern Med 140 (2004) 265-268
11. Lang R.M., et al., on behalf of the Chamber Quantification Writing Group. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18 (2005) 1440-1463
12. Berkowitsch A., Greiss H., Vukajlovic D., et al. Usefulness of atrial fibrillation burden as a predictor for success of pulmonary vein isolation. Pacing Clin Electrophysiol 28 (2005) 1292-1301
13. Darbar D., and Roden D.M. Symptomatic burden as an endpoint to evaluate interventions in patients with atrial fibrillation. Heart Rhythm 2 (2005) 544-549
14. Euler D.E., and Freidman P.A. Atrial arrhythmia burden as an endpoint in clinical trials: is the best surrogate? Lessons from a multicenter defibrillator trial. Card Electrophysiol Rev 7 (2003) 355-358
15. Goette A., Arndt M., Rocken C., et al. Calpains and cytokines in fibrillating human atria. Am J Physiol Heart Circ Physiol 283 (2002) H264-H272
16. Cordis G.A., Maulik N., and Das D.K. Detection of oxidative stress in heart by estimating the dinitrophenylhydrazine derivative malonaldehyde. J Mol Cell Cardiol 27 (1995) 1645-1653
17. Andreadou I., Iliodromitis E.K., Tsovolas K., et al. Acute administration of vitamin E triggers preconditioning via K(ATP) channels and cyclic-GMP without inhibiting lipid peroxidation. Free Radic Biol Med 41 (2006) 1092-1099
18. Maixent J.M., Paganelli F., Scaglione J., and Levy S. Antibodies against myosin in sera of patients with idiopathic paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol 9 (1998) 612-617
19. von Haehling S., Jankowska E.A., and Anker S.D. Tumor necrosis factor-a and the failing heart. Pathophysiology and therapeutic implications. Basic Res Cardiol 99 (2004) 18-28
20. Tveit A., Seljeflot I., Grundvold I., et al. Effect of candesartan and various inflammatory markers on maintenance of sinus rhythm after electrical cardioversion for atrial fibrillation. Am J Cardiol 99 (2007) 1544-1548
21. Saba S., Janczewski A.M., Baker L.C., et al. Atrial contractile dysfunction, fibrosis, and arrhythmias in a mouse model of cardiomyopathy secondary to cardiac-specific overexpression of tumor necrosis factor-a. Am J Physiol Heart Circ Physiol 289 (2005) H1456-H1467
22. Ishida K., Kimura F., Imamaki M., et al. Relation of inflammatory cytokines to atrial fibrillation after off-pump coronary artery bypass grafting. Eur J Cardiothorac Surg 29 (2006) 501-505
23. Adamopoulos S., Parissis J., and Kremastinos D.T. A glossary of circulating cytokines in chronic heart failure. Eur J Heart Fail 3 (2001) 517-526
24. Stouthard J.M., Romijn J.A., Van der Poll T., et al. Endocrinologic and metabolic effects of interleukin-6 in humans. Am J Physiol 268 (1995) E813-E819
25. Dimmer C., Tavernier R., Gjorgov N., Van Nooten G., Glement D.L., and Jordaens L. Variations of autonomic tone preceding onset of atrial fibrillation after coronary artery bypass grafting. Am J Cardiol 82 (1998) 22-25
26. Moore K.W., de Waal Malefyt R., Caffman R.L., and O'Garra A. Inteleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19 (2001) 683-765
27. Chen M.C., Chang H.W., Juang S.S., et al. Percutaneous transluminal mitral valvuloplasty reduces circulating vascular cell adhesion molecule-1 in rheumatic mitral stenosis. Chest 125 (2004) 1213-1217
28. Mihm M.J., Coyle C., Schanbacher B.L., et al. Peroxynitrite induced nitration and inactivation of myofibrillar creatine kinase in experimental heart failure. Cardiovasc Res 49 (2001) 798-807
29. Barouch L.A., Harrison R.W., Skaf M.W., et al. Nitric oxide regulates the heart by spatial confinement of nitric oxide synthase isoforms. Nature 416 (2002) 337-339
30. Anderson J.L., Allen Maycock C.A., Lappe D.L., et al., Intermountain Heart Collaborative Study group. Frequency of elevation of C-reactive protein in atrial fibrillation. Am J Cardiol 94 (2004) 1255-1259
31. Aviles R.J., Martin D.O., Apperson-Hansen C., et al. Inflammation as a risk factor for atrial fibrillation. Circulation 108 (2003) 3006-3010
32. Ellinor P.T., Low A., Patton K.K., Shea M.A., and MacRae C.A. C-reactive protein in lone atrial fibrillation. Am. J. Cardiol 97 (2006) 1346-1250
33. Flaker G.C., Fletcher K.A., Rothbart R.M., Halperin J.L., and Hart R.G. Clinical and echocardiographic features of intermittent atrial fibrillation that predict recurrent atrial fibrillation. Stroke Prevention in Atrial Fibrillation (SPAF) investigators. Am J Cardiol 76 (1995) 355-358
34. Olshansky B., Heller E.N., Mitchell L.B., et al. Results from the atrial fibrillation follow-up investigation of rhythm management (AFFIRM) study. J Am Coll Cardiol 45 (2005) 2026-2033
35. Antonielli E., Pizzuti A., Palinkas A., et al. Clinical value of left atrial appendage flow for prediction of long-term sinus rhythm maintenance in patients with nonvalvular atrial fibrillation. J Am Coll Cardiol 39 (2002) 1443-1449
36. Tanabe T., Deguchi Y., Handa S., Takahashi A., and Fukushi H. Longer longitudinal atrial dimension in patients with idiopathic paroxysmal atrial fibrillation: a possible cause of atrial fibrillation. Am Heart J 142 (2001) 669-678
37. Cui Q., Zhang W., Wang H., et al. Left and right atrial size and the occurrence predictors in patients with paroxysmal atrial fibrillation. Int J Cardiol 130 (2008) 69-71
38. Mattioli A.V., Bonatti S., Bonetti L., and Mattioli G. Left atrial size after cardioversion for atrial fibrillation: effect of external direct current shock. J Am Soc Echocardiogr 16 (2003) 271-276
39. Mattioli A.V., Sansoni S., Lucchi G.R., and Mattioli G. Serial evaluation of left atrial dimension after cardioversion for atrial fibrillation and relation to atrial function. Am J Cardiol 85 (2000) 832-836